Fold change of TIL subsets in paired TNBCs (N = 12 pts including 10 prim-met, and 2 met-met specimens) using log2 ratio of metastatic versus primary TNBC (n = 10, ●) or second recu... by Ting-Fang He (5210948)

Recovery coefficient. by Masakazu Tsujimoto (22339504)

Subjects:

Results of dose linearity. by Masakazu Tsujimoto (22339504)

Subjects:

NEMA IEC body phantom. by Masakazu Tsujimoto (22339504)

Subjects:

Relationship between contrast, noise, and CNR. by Masakazu Tsujimoto (22339504)

Subjects:

JS-10 phantom. by Masakazu Tsujimoto (22339504)

Subjects:

Illustrations of the SeqFold2D network and the Stralign dataset. by Xiangyun Qiu (316117)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases breadth of Env-specific IgG response. by LaTonya D. Williams (3140490)

Average value of cost components composing the unit cost (in USD) of SARS-CoV-2 diagnosis per per device type. by Nelmo Jordão Manjate (16324619)

Subjects:

Fig 5 - by Dennis Ochola (11626912)

Subjects:

Antibody response elicited by SARS-CoV-2 vaccines. by Chris Davis (647632)

Subjects:

Table_5_Sub-Inhibitory Concentrations of Chlorhexidine Induce Resistance to Chlorhexidine and Decrease Antibiotic Susceptibility in Neisseria gonorrhoeae.DOCX by Jolein G. E. Laumen (11754755)

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

Synthesis and Antiproliferative Activity of a New Series of Mono- and Bis(dimethylpyrazolyl)‑<i>s</i>‑triazine Derivatives Targeting EGFR/PI3K/AKT/mTOR Signaling Cascades by Ihab Shawish (13015516)

“…The antiproliferative activity of the novel <i>mono</i>- and <i>bis</i>(dimethylpyrazolyl)-<i>s</i>-triazine derivatives was studied against three cancer cell lines, namely, MCF-7, HCT-116, and HepG2. <i>N</i>-(4-Bromophenyl)-4-(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-6-morpholino-1,3,5-triazin-2-amine <b>4f</b>, <i>N</i>-(4-chlorophenyl)-4,6-bis­(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-1,3,5-triazin-2-amine <b>5c</b>, and 4,6-<i>bis</i>(3,5-dimethyl-1<i>H</i>-pyrazol-1-yl)-<i>N</i>-(4-methoxyphenyl)-1,3,5-triazin-2-amine <b>5d</b> showed promising activity against these cancer cells: <b>4f</b> [(IC₅₀ = 4.53 ± 0.30 μM (MCF-7); 0.50 ± 0.080 μM (HCT-116); and 3.01 ± 0.49 μM (HepG2)]; <b>5d</b> [(IC₅₀ = 3.66 ± 0.96 μM (HCT-116); and 5.42 ± 0.82 μM (HepG2)]; and <b>5c</b> [(IC₅₀ = 2.29 ± 0.92 μM (MCF-7)]. …”

Age-stage-specific reproductive values (<i>v</i>_<i>xj</i>) of <i>A</i>. <i>glycines</i>. by Aonan Zhang (8933630)

The position of the mutations I989T, V992M and V997M in the ACE C domain. by Olga V. Kryukova (19819428)

Subjects:

Loss of Prox1a decreases PR production at 120 hours post-ablation. by Kellie Veen (17343374)

The human neutrophil IL-1β secretory response, in contrast to the CXCL8/IL-8 secretory response decreases as MOI increases. by Florencia Sabbione (4862455)

Exercise test characteristics for identifying stenosis ≥ 50% in any limb among the 60 limbs with normal ABIs (> 0.91). by O. Stivalet (6890189)

Extracted ion chromatogram of azoxystrobin 50 ppb, injection volume of 2, 5, and 25 μL. by Ekramy Halawa (11785086)